Skip to content

Clinical trials

Completed Tuberculosis trials in India

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Tuberculosis Status: Completed Country / region: India Clear all

43 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20021
20051
20064
20073
20082
20092
20103
20112
20121
20131
20142
20152
20163
20171
20181
20198
20203
20211
20241

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed43

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
All India Institute of Medical Sciences8
National Institute of Allergy and Infectious Diseases (NIAID)5
Post Graduate Institute of Medical Education and Research, Chandigarh4
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections2
Centers for Disease Control and Prevention2
Foundation for Innovative New Diagnostics, Switzerland2
Ministry of Science and Technology, India2
Médecins Sans Frontières, France2
Aeras1
Bharat Biotech International Limited1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Tuberculosis43
HIV Infections7
Tuberculosis, Multidrug-Resistant7
Tuberculosis, Pulmonary5
Extensively Drug-Resistant Tuberculosis3
Latent Tuberculosis3
Acquired Immunodeficiency Syndrome2
Bacterial Infections2
Hepatitis2
Malnutrition2

Trials

Showing 1 to 25 of 43. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.